Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly is experiencing explosive growth thanks ... that it is acquiring a clinical stage drug known as STX-478 from Scorpion Therapeutics for up to $2.5 billion. Lilly's long-term potential ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE ... a clinical stage drug known as STX-478 from Scorpion Therapeutics for up to $2.5 billion.

I think the company's clinical pipeline and recent acquisition from Scorpion really drive home ... best stocks for investors to buy now… and Eli Lilly wasn’t one of them.

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

As we wrap up JPMorgan 2025, another huge congratulations to the Scorpion team for its $2.5B acquisition by Eli Lilly to access its mutPI3Ka inhibitor STX-478. The quality of the work at Scorpion ...

Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...